Legal Representation
Attorney
Kimberly Gambrel
USPTO Deadlines
Next Deadline
845 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-11-02)
Due Date
November 02, 2027
Grace Period Ends
May 02, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
31 events| Date | Code | Type | Description |
|---|---|---|---|
| Nov 2, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Aug 17, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Aug 17, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Jul 28, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Jul 15, 2021 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jun 23, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Jun 23, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jun 23, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Apr 2, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Apr 2, 2021 | GNRT | O | NON-FINAL ACTION E-MAILED |
| Apr 2, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Mar 8, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Mar 8, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Mar 4, 2021 | ALIE | A | ASSIGNED TO LIE |
| Feb 25, 2021 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Jan 27, 2021 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Nov 30, 2020 | CNSL | R | SUSPENSION LETTER WRITTEN |
| Nov 30, 2020 | GNSL | S | LETTER OF SUSPENSION E-MAILED |
| Nov 30, 2020 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Nov 24, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Nov 24, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Nov 19, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Oct 5, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Oct 5, 2020 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Oct 5, 2020 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Sep 29, 2020 | DOCK | D | ASSIGNED TO EXAMINER |
| Jul 23, 2020 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Jul 23, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Jul 14, 2020 | ALIE | A | ASSIGNED TO LIE |
| Jul 2, 2020 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Jun 30, 2020 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
pharmaceutical preparations for pain, cancer, autoimmune disease, inflammatory disease, neurological disease, psychiatric disease, cardiovascular disease, metabolic disease, endocrine disease, musculoskeletal disease, genetic disease, gastrointestinal disease, haematological disease, respiratory disease, infectious disease, ophthalmological disease, renal disease, hepatic disease, urological disease, gynaecological disease, dermatological disease; Medical preparations for pain, cancer, autoimmune disease, inflammatory disease, neurological disease, psychiatric disease, cardiovascular disease, metabolic disease, endocrine disease, musculoskeletal disease, genetic disease, gastrointestinal disease, haematological disease, respiratory disease, infectious disease, ophthalmological disease, renal disease, hepatic disease, urological disease, gynaecological disease, dermatological disease; Veterinary preparations for cats, dogs, pets, livestock
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
scientific research in the pharmaceutical field; pharmaceutical research and development services; providing scientific research information in the field of pharmaceutical research and development
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005
042